Securities Registration: Employee Benefit Plan (s-8)
16 August 2019 - 11:02PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission
on August 16, 2019
Registration
No. 333-
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
________________
NeuBase Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
46-5622433
|
(State
or other jurisdiction of
incorporation or organization)
|
(I.R.S.
Employer
Identification No.)
|
|
|
700
Technology Drive, Third Floor
Pittsburgh,
Pennsylvania
|
15219
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
________________
2019
Stock Incentive Plan
(Full
title of the plan)
Dr.
Dietrich Stephan
President
and Chief Executive Officer
NeuBase
Therapeutics, Inc.
700
Technology Drive, Third Floor
Pittsburgh,
Pennsylvania 15219
(Name
and address of agent for service)
(646)
450-1790
(Telephone
number, including area code, of agent for service)
________________
Copies
of all correspondence to:
Jeffrey T. Hartlin, Esq.
Paul Hastings LLP
1117 S. California Avenue
Palo Alto, California 94304
(650) 320-1800
________________
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer
|
☐
|
Accelerated
filer
|
☐
|
Non-accelerated
filer
|
☒
|
Smaller
reporting company
|
☒
|
|
|
Emerging
growth company
|
☐
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION
OF REGISTRATION FEE
Title
of securities
to be registered
|
Amount
to
be registered
(1)
|
Proposed
maximum
offering price
per share
|
Proposed
maximum
aggregate offering
price
|
Amount
of
registration fee
|
Common
Stock, $0.0001 par value per share, reserved for issuance under the Plan (as defined below)
|
2,917,519
(2)
|
$5.39
(3)
|
$15,725,427.41
(3)
|
$1,905.93
|
Common
Stock, $0.0001 par value per share, reserved for issuance under the Plan (as defined below)
|
182,481
(4)
|
$5.09
(5)
|
$928,828.29
(5)
|
$112.58
|
(1)
|
Pursuant
to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration
Statement on Form S-8 (the “Registration Statement”) also covers an indeterminate number of additional shares
of common stock, $0.0001 par value per share (the “Common Stock”) of NeuBase Therapeutics, Inc. (f/k/a Ohr Pharmaceutical,
Inc.) (the “Registrant”) that become issuable under the Registrant’s 2019 Stock Incentive Plan (the “Plan”),
by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration
that increases the number of the Registrant’s outstanding shares of Common Stock.
|
(2)
|
Represents
shares of Common Stock issuable pursuant to outstanding but unexercised stock options previously granted under the Plan.
|
(3)
|
Estimated
solely for the purpose of calculating the amount of the registration fee pursuant to Rules 457(h) of the Securities Act. The
proposed maximum aggregate offering price per share and the proposed maximum aggregate offering price with respect to these
shares are calculated based on the weighted average exercise price of the outstanding options.
|
(4)
|
Represents
shares of Common Stock issuable pursuant to awards to be issued under the Plan.
|
(5)
|
Estimated
solely for the purpose of calculating the registration fee and computed in accordance with Rule 457(c) and (h) under
the Securities Act using the average of the high and low sale prices of the Common Stock as reported on The NASDAQ Capital
Market on August 14, 2019, which was $5.09 per share of Common Stock.
|
PART
I
INFORMATION
NOT REQUIRED IN THE SECTION 10(a) PROSPECTUS
The
document(s) containing the information specified in Part I will be sent or given to employees as specified by Rule 428(b)(1) of
the Securities Act. Such documents are not being filed with the Securities and Exchange Commission (the “Commission”)
either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities
Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof,
taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
PART
II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3.
|
Incorporation of Documents by Reference
.
|
The
Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant
with the Commission:
|
●
|
the
Registrant’s Annual Report on Form 10-K (No. 001-35963) for the fiscal year
ended September 30, 2018, filed with the Commission on January 3, 2019;
|
|
●
|
the
Registrant’s Quarterly Reports on Form 10-Q (No. 001-35963) for the quarters ended
December 31, 2018, March 31, 2019 and June 30, 2019, filed with the Commission on February
14, 2019, May 15, 2019 and August 14, 2019, respectively;
|
|
●
|
the
Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission
on December 12, 2018;
|
|
●
|
the
Registrant’s Current Reports on Form 8-K (No. 001-35963) filed with the Commission
on October 4, 2018, January 3, 2019, January 23, 2019, February 26, 2019, May 15,
2019, July 3, 2019, July 10, 2019, and July 12, 2019;
|
|
●
|
the
Registrant’s Current Reports on Form 8-K/A filed with the Commission on July 11,
2019 and July 17, 2019; and
|
|
●
|
the
description of the Registrant’s Common Stock, contained in the Registrant’s
Registration Statement on Form 8-A (No. 001-35963), filed with the Commission on
June 11, 2013, including any amendments or reports filed for the purpose of updating
such description.
|
All
documents that the Registrant subsequently filed pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities and Exchange
Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment to this Registration
Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining
unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of
the filing of such documents
, except as to any portion of any future annual or quarterly
report to stockholders or document or current report furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed
filed under such provisions.
Any
statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified
or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is
deemed to be incorporated by reference herein modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute
a part of this Registration Statement.
Notwithstanding
the above, information that is “furnished to” the Commission shall not be deemed “filed with” the Commission
and shall not be deemed incorporated by reference into this Registration Statement.
You
should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus.
The Registrant has not authorized anyone to provide you with different information. You should not assume that the information
in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.
You
may contact the Registrant in writing or orally to request copies of the above-referenced filings, without charge (excluding exhibits
to such documents unless such exhibits are specifically incorporated by reference into the information incorporated into this
Registration Statement). Requests for such information should be directed to:
NeuBase
Therapeutics, Inc.
700
Technology Drive, Third Floor
Pittsburgh,
PA 15219
(646)
450-1790
Attn:
Chief Financial Officer
ITEM 4.
|
Description of Securities
.
|
Not
applicable.
ITEM 5.
|
Interests
of Named Experts and Counsel
.
|
Not
applicable.
ITEM 6.
|
Indemnification
of Directors and Officers
.
|
The
Registrant is a Delaware corporation. Reference is made to Section 102(b)(7) of the General Corporation Law of the State of Delaware
(the “DGCL”), which enables a corporation in its original certificate of incorporation or an amendment thereto to
eliminate or limit the personal liability of a director for violations of the director’s fiduciary duty, except (1) for
any breach of the director’s duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good
faith or which involve intentional misconduct or a knowing violation of law, (3) pursuant to Section 174 of the DGCL (providing
for liability of directors for unlawful payment of dividends or unlawful stock purchase or redemptions), or (4) for any transaction
from which a director derived an improper personal benefit.
Reference
also is made to Section 145 of the DGCL, which provides that a corporation may indemnify any persons, including officers and directors,
who are, or are threatened to be made, parties to any threatened, pending or completed legal action, suit or proceeding, whether
civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the
fact that such person was an officer, director, employee or agent of such corporation or is or was serving at the request of such
corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses
(including attorney’s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person
in connection with such action, suit or proceeding, provided such officer, director, employee or agent acted in good faith and
in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interest and, for criminal proceedings,
had no reasonable cause to believe that his or her conduct was unlawful. A Delaware corporation may indemnify officers and directors
in an action by or in the right of the corporation under the same conditions, except that no indemnification is permitted without
judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful
on the merits or otherwise in the defense
of any action referred to above, the corporation must indemnify him against the expenses that such officer or director actually
and reasonably incurred.
The
Registrant’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”),
eliminates the personal liability of directors to the fullest extent permitted by the DGCL and provides that the Registrant (1)
shall indemnify and advance expenses to any person made or threatened to be made a party to an action, suit or proceeding, whether
criminal, civil, administrative or investigative, by reason of the fact that he or she, or his or her testator or intestate, is
or was a director or officer of the Registrant or any predecessor of the Registrant, or serves or served at any other enterprise
as a director or officer at the request of the Registrant or any predecessor to the Registrant and (2) may indemnify and advance
expenses to any person made or threatened to be made a party to an action, suit or proceeding, whether criminal, civil, administrative
or investigative, by reason of the fact that he or she, or his or her testator or intestate, is or was an employee or agent of
the Registrant or any predecessor of the Registrant, or serves or served at any other enterprise as an employee or agent at the
request of the Registrant or any predecessor to the Registrant.
The
Registrant has an insurance policy that insures its directors and officers, within the limits and subject to the limitations of
the policy, against certain expenses in connection with the defense of actions, suits or proceedings, and certain liabilities
that might be imposed as a result of such actions, suits or proceedings, to which they are parties by reason of being or having
been directors or officers.
The
Registrant has indemnification agreements with each of its directors and executive officers that may be broader than the specific
indemnification provisions contained in the
DGCL
.
These indemnification agreements require the Registrant, among other things, to indemnify a director or officer, to the fullest
extent permitted by applicable law, for certain expenses, including attorneys’ fees, judgments, penalties, fines and settlement
amounts actually and reasonably incurred by them in any action or proceeding arising out of their services as one of a director
or officer of the Registrant, or any of the Registrant’s subsidiaries or any other company or enterprise to which the person
provides services at the Registrant’s request, including liability arising out of negligence or active or passive misconduct
by the director or officer. The Registrant believes that these agreements are necessary to attract and retain qualified individuals
to serve as directors and executive officers.
ITEM 7.
|
Exemption
from Registration Claimed
.
|
Not
applicable.
Reference
is made to the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this
Registration Statement, which Exhibit Index is incorporated herein by reference.
(a)
The
undersigned Registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)
To include any prospectus required by section 10(a)(3) of the Securities Act;
(ii)
To
reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most
recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the
information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities
offered
(if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement
or any material change to such information in the Registration Statement;
provided,
however,
that paragraphs (a)(1)(i) and (a)(1)(ii) of this section shall not apply if the information required to be included
in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant
pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement;
(2)
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
(b)
The
undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing
of the Registrant’s annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable,
each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated
by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(h)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant
has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the
securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of Pittsburgh and the State of Pennsylvania, on August
16, 2019.
|
NEUBASE
THERAPEUTICS, INC.
|
|
|
|
By:
|
/s/ Dr. Dietrich Stephan
|
|
|
|
Dr. Dietrich Stephan
|
|
|
President and Chief Executive Officer
|
POWER
OF ATTORNEY
KNOW
ALL PERSONS BY THESE PRESENTS, that each of Dr. Dov A. Goldstein, Dr. Diego Miralles, Dr. Franklyn G. Prendergast and Mr. Eric
I. Richman constitutes and appoints Dr. Dietrich Stephan and Mr. Sam Backenroth, and each of them, and that Dr. Dietrich Stephan
constitutes and appoints Mr. Sam Backenroth, and that Mr. Sam Backenroth constitutes and appoints Dr. Dietrich Stephan, as his
true and lawful attorney-in-fact and agent, upon the action of such appointee, with full power of substitution and resubstitution,
to do any and all acts and things and execute, in the name of the undersigned, any and all instruments which each of said attorneys-in-fact
and agents may deem necessary or advisable in order to enable the Registrant to comply with the Securities Act of 1933, as amended
(the “Securities Act”), and any requirements of the Securities and Exchange Commission (the “Commission”)
in respect thereof, in connection with the filing with the Commission of this Registration Statement on Form S-8 under the
Securities Act, including specifically but without limitation, power and authority to sign the name of the undersigned to such
Registration Statement, and any amendments to such Registration Statement (including post-effective amendments), and to file
the same with all exhibits thereto and other documents in connection therewith, with the Commission, to sign any and all applications,
Registration Statements, notices or other documents necessary or advisable to comply with applicable state securities laws, and
to file the same, together with other documents in connection therewith with the appropriate state securities authorities, granting
unto each of said attorneys-in-fact and agents full power and authority to do and to perform each and every act and thing requisite
or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could
do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents may lawfully do or cause to be
done by virtue hereof.
Pursuant
to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities
and on the dates indicated.
Signature
|
Title
|
Date
|
|
|
|
/s/
Dr. Dietrich Stephan
|
President
and Chief Executive Officer and Director
|
August
16, 2019
|
Dr.
Dietrich Stephan
|
(Principal
Executive Officer)
|
|
|
|
|
/s/
Mr. Sam Backenroth
|
Chief
Financial Officer, Treasurer and Secretary
|
August
16, 2019
|
Mr.
Sam Backenroth
|
(Principal
Financial and Accounting Officer)
|
|
|
|
|
/s/
Dr. Dov A. Goldstein
|
Director
|
August
16, 2019
|
Dr.
Dov A. Goldstein
|
|
|
|
|
|
/s/
Dr. Diego Miralles
|
Director
|
August
16, 2019
|
Dr.
Diego Miralles
|
|
|
|
|
|
/s/
Dr. Franklyn G. Prendergast
|
Director
|
August
16, 2019
|
Dr.
Franklyn G. Prendergast
|
|
|
|
|
|
/s/
Mr. Eric I. Richman
|
Director
|
August
16, 2019
|
Mr.
Eric I. Richman
|
|
|
EXHIBIT
INDEX
Exhibit Number
|
|
Description
|
|
|
|
4.1(a)
|
|
Form
of Class J Common Stock Purchase Warrant issued on December 16, 2011 (incorporated herein by reference to Exhibit 10.25 to
the Registrant’s Current Report on Form 8-K, filed on December 20, 2011)
|
|
|
|
4.1(b)
|
|
Amendment,
dated March 11, 2014, to Class J Common Stock Purchase Warrants (incorporated herein by reference to Exhibit 10.39 to the
Registrant’s Current Report on Form 8-K, filed on March 14, 2014)
|
|
|
|
4.2
|
|
Form
of Consulting Warrants (incorporated herein by reference to Exhibit 10.21 to the Registrant’s Quarterly Report on Form
10-Q, for the fiscal quarter ended June 30, 2011, filed on August 15, 2011)
|
|
|
|
4.3
|
|
Form
of Series A Warrant (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K,
filed on December 8, 2016)
|
|
|
|
4.4
|
|
Form
of Warrant (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on
April 6, 2017)
|
|
|
|
4.5
|
|
Ohr
Pharmaceutical, Inc. 2019 Stock Incentive Plan (incorporated herein by reference to Annex E to the Registrant’s Registration
Statement on Form S-4, as amended, filed on June 3, 2019)
|
|
|
|
4.6
|
|
Form
of Option Agreement under the Ohr Pharmaceutical, Inc. 2019 Stock Incentive Plan
|
|
|
|
4.7
|
|
NeuBase
Therapeutics, Inc. 2018 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.19 to the Registrant’s
Registration Statement on Form S-4, filed on March 8, 2019)
|
|
|
|
4.8
|
|
Form
of Option Agreement under the NeuBase Therapeutics, Inc. 2018 Equity Incentive Plan
|
|
|
|
4.9
|
|
Ohr
Pharmaceutical, Inc. 2016 Consolidated Stock Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s
Current Report on Form 8-K, filed on March 21, 2016)
|
|
|
|
4.10
|
|
Form
of Stock Option Agreement under the Ohr Pharmaceutical, Inc. 2016 Consolidated Stock Incentive Plan (incorporated herein by
reference to Exhibit 10.11(b) to the Registrant's Form 10-K, for the fiscal year ended September 30, 2017, filed on December
15, 2017)
|
|
|
|
4.11
|
|
Form
of Restricted Stock Agreement under the Ohr Pharmaceutical, Inc. 2016 Consolidated Stock Incentive Plan (incorporated herein
by reference to Exhibit 10.11(c) to the Registrant's Form 10-K, for the fiscal year ended September 30, 2017, filed on December
15, 2017)
|
|
|
|
4.12(a)
|
|
Ohr
Pharmaceutical, Inc. 2014 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.42 to the Registrant’s
Current Report on Form 8-K, filed on April 14, 2014)
|
4.12(b)
|
|
Amendment
to Ohr Pharmaceutical, Inc. 2014 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.8(b) to the Registrant’s
Annual Report on Form 10-K, for the fiscal year ended September 30, 2015, filed on December 14, 2015)
|
|
|
|
4.13
|
|
Form
of Stock Option Agreement under the Ohr Pharmaceutical, Inc. 2014 Stock Incentive Plan (incorporated herein by reference to
Exhibit 10.53 to the Registrant's Form 10-Q, for the fiscal quarter ended March 31, 2015, filed on May 11, 2015)
|
|
|
|
4.14
|
|
Ohr
Pharmaceutical, Inc. 2009 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s
Form 10-Q, for the fiscal quarter ended March 31, 2010, filed on May 17, 2010)
|
|
|
|
4.15
|
|
Form
of Ohr Pharmaceutical, Inc. and NeuBase Therapeutics, Inc. Lock-Up Agreements (incorporated herein by reference to Exhibit
2.4 to the Registrant’s Current Report on Form 8-K, filed on January 3, 2019)
|
|
|
|
4.16
|
|
Registration
Rights Agreement, dated July 12, 2019, by and among the Registrant and certain investors named therein (incorporated herein
by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on July 12, 2019)
|
|
|
|
4.17
|
|
Form
of Common Stock Certificate
|
|
|
|
5.1
|
|
Opinion
of Paul Hastings LLP
|
|
|
|
23.1
|
|
Consent
of MaloneBailey, LLP, Independent Registered Public Accounting Firm
|
|
|
|
23.2
|
|
Consent
of Paul Hastings LLP (included in Exhibit 5.1 of this Registration Statement)
|
|
|
|
24.1
|
|
Power
of Attorney (included on signature page of this Registration Statement)
|
Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024